
TMO Stock Forecast & Price Target
TMO Analyst Ratings
Bulls say
Thermo Fisher Scientific is projected to experience revenue growth across its segments, with lab products and services (LPBS) anticipated to expand at a compound annual growth rate (CAGR) of 5.4% over the next three years, despite a prior rate of 16.9% from 2019 to 2024. The company's analytical instruments segment is expected to grow at a more moderate CAGR of 2.5%, reflecting a shift in market dynamics while still contributing positively to the overall performance. Additionally, an 8.5% CAGR in adjusted earnings per share (EPS) over the next four years indicates a robust financial outlook driven by growth initiatives and strategic positioning within the clinical research organization (CRO) market.
Bears say
Thermo Fisher Scientific has experienced a significant decline in its adjusted EBIT margin, which fell by approximately 830 basis points to 22.6% from 2021 to 2024, driven by a sharp reduction in adjusted gross margin that decreased by around 940 basis points to 42.2%. This decline has placed the company's margins below pre-pandemic levels, with the adjusted gross margin currently about 420 basis points lower than the 46.4% recorded in 2019. Additionally, despite recent claims of improved biotech customer sentiment, early-stage funding in 2025 is lagging, with a 45% year-over-year decrease in capital raised, raising concerns about future revenue growth.
This aggregate rating is based on analysts' research of Thermo Fisher Scientific and is not a guaranteed prediction by Public.com or investment advice.
TMO Analyst Forecast & Price Prediction
Start investing in TMO
Order type
Buy in
Order amount
Est. shares
0 shares